AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
This rating reflects Lupin's leadership in environmental transparency and performance
Subscribe To Our Newsletter & Stay Updated